Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Divestments (2013 - 2023)

Harvard Bioscience (HBIO) reported Divestments of $512000.0 for Q1 2023, up 2944.44% on a QoQ basis from -$18000.0 in Q4 2019.

Harvard Bioscience (HBIO) has 5 years of Divestments data on file, last reported at $512000.0 in Q1 2023.

  • Quarterly Divestments changed N/A year-over-year to $512000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $512000.0 (changed N/A YoY) and the FY2023 annual result came in at $512000.0, changed N/A from the prior year.
  • Divestments climbed to $512000.0 in Q1 2023 per HBIO's latest filing, from -$18000.0 in the prior quarter.
  • Across five years, Divestments topped out at $1.0 million in Q2 2019 and bottomed at -$18000.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn -
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn -
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn -
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn -
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn -
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn -
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn -
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn -
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 512,000.00
Dec 31, 2019 -18,000.00
Jun 30, 2019 1.02 Mn
Jun 30, 2018 24,000.00
Mar 31, 2018 15.73 Mn
Mar 31, 2014 1.80 Mn
Dec 31, 2013 75,000.00